2025-12-19 - Analysis Report
Okay, here's a comprehensive analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the provided data.

**1) Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering.
*   **RXRX Cumulative Return:** -28.11%
*   **VOO Cumulative Return:** 41.08%
*   **Divergence:** -73.8 (Relative Divergence: 0.4)

**Analysis:** RXRX has significantly underperformed the S&P 500. The divergence of -73.8 is substantial. The relative divergence of 0.4 indicates that the current divergence is very close to its minimum point of past fluctuation. The analysis of Alpha, Beta, CAGR, MDD data indicates that the RXRX's performance is declining over time. Specifically, Alpha is declining over time.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha   | Beta  | Cap(B) |
|------------|-------|-------|---------|-------|--------|
| 2021-2023  | 22.0% | 81.0% | 26.0%   | -0.2  | 5.1    |
| 2022-2024  | 11.0% | 81.0% | -10.0%  | 0.1   | 3.5    |
| 2023-2025  | 14.0% | 80.0% | -49.0%  | 0.1   | 2.3    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows positive growth, but it varies.
*   **MDD:** The Maximum Drawdown is consistently high, indicating substantial risk and volatility.
*   **Alpha:** Alpha has decreased significantly, suggesting RXRX is generating increasingly lower risk-adjusted returns compared to its benchmark.
*   **Beta:** Beta values are close to zero, which means that it is hard to determine if the stock is sensitive to market movements.
*   **Cap(B):** The market capitalization has decreased, meaning that the size of the company is shrinking.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 4.44
*   **Previous Close:** 4.68
*   **Change:** -5.13%
*   **5-day SMA:** 4.37
*   **20-day SMA:** 4.4773
*   **60-day SMA:** 5.0279

**Analysis:** The stock is currently trading below its 5-day and 20-day moving averages, suggesting a short-term downtrend. The 60-day SMA is significantly higher, indicating that the price has been declining recently. The -5.13% change from the previous close signifies a notable downward move.

**3) Technical Indicators and Expected Return**

*   **MRI:** 0.7 (Medium Investment Recommended)
*   **RSI:** 45.41 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.3474 (Positive, but close to zero - indicating a weak upward trend)
*   **Hybrid Signal:** Buy signal (225 shares - Very Safe - MRI:0.90), suggesting a small monthly investment.
*   **Recent Relative Divergence Change:** -4.7 (Short-term decline)
*   **Expected Return:** -540.8% (Very Negative)

**Analysis:** The MRI suggests a medium investment risk. The RSI is neutral. The PPO indicates a weak upward trend. Despite a buy signal from the Hybrid Signal, the expected return is extremely negative, signaling significant potential downside risk in the long term. The recent decline in relative divergence reinforces the short-term negative momentum.

**4) Recent News & Significant Events**

*   **JPMorgan Upgrade:** Several news articles highlight an upgrade by JPMorgan, citing REC-4881 trial momentum.
*   **Stock Dive Analysis:** Other articles analyze the recent stock price dive and its impact.

**Analysis:** The JPMorgan upgrade is a positive catalyst and could lead to short-term gains. However, the articles also mention the recent price dive, indicating potential underlying concerns. This creates a mixed picture.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.50 ~ Hold)
*   **Opinions:** 7
*   **Target Price:** Avg: 7.00 / High: 11.00 / Low: 3.00

**Analysis:**  Analysts, on average, rate RXRX as a "Hold" but with a "Buy" recommendation. The average target price of $7.00 suggests potential upside from the current price of $4.44. However, there is a wide range in target prices ($3.00 - $11.00), indicating uncertainty among analysts.  No recent rating changes are provided.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-11-05 | -0.36 | 0.01 B$  |
| 2025-08-05 | -0.41 | 0.02 B$  |
| 2025-05-05 | -0.50 | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2025-11-05 | -0.34 | 0.03 B$  |

**Analysis:** RXRX is consistently losing money. EPS is negative in each of the reported quarters. While revenue fluctuates, it remains low, suggesting the company is struggling to generate significant income. EPS is not improving over time.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.00B  | -194.74%      |
| 2025-06-30   | $0.02B  | -5.54%        |
| 2025-03-31   | $0.01B  | -47.31%       |
| 2024-12-31   | $0.00B  | -183.62%      |
| 2024-09-30   | $0.03B  | 53.69%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-09-30   | $1.05B  | -15.50%  |
| 2025-06-30   | $0.92B  | -18.70%  |
| 2025-03-31   | $0.93B  | -21.68%  |
| 2024-12-31   | $1.03B  | -17.29%  |
| 2024-09-30   | $0.52B  | -18.27%  |

**Analysis:**

*   **Revenue:** Revenue generation is inconsistent and low. Two quarters show $0 revenue.
*   **Profit Margin:** Profit margins are overwhelmingly negative, indicating the company is spending significantly more than it earns.
*   **Equity:** Equity is relatively stable but slightly decreasing, indicating the value of the company is shrinking.
*   **ROE:** Return on Equity is consistently negative, confirming the company's poor profitability.

**7) Comprehensive Analysis**

Recursion Pharmaceuticals Inc. (RXRX) presents a mixed picture.

*   **Negative Factors:**
    *   **Significant Underperformance:** RXRX has severely underperformed the S&P 500.
    *   **Negative Expected Return:** The very negative expected return (-540.8%) is a major red flag.
    *   **Consistent Losses:** EPS and Profit Margins are consistently negative, revealing a lack of profitability.
    *   **Short-Term Downtrend:** The stock is currently trading below its short-term moving averages.
    *   **High MDD:** The consistently high MDD indicates substantial risk and volatility.
*   **Positive Factors:**
    *   **JPMorgan Upgrade:** The recent upgrade by JPMorgan could provide a short-term boost.
    *   **Analyst Consensus:** Analyst consensus is "Buy" which provides hope on the stock.

**Conclusion:**

Investing in RXRX is highly risky. While the JPMorgan upgrade and analyst ratings offer some hope, the company's financial performance is weak, its stock is underperforming, and technical indicators raise concerns. Before investing, investors should carefully consider their risk tolerance and the potential for further losses.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.